Schistosomiasis/bilharziasis in preschool and school children along shores and on islands of Lake Victoria western Kenya: identifying suitable markers for monitoring the progress of bilharzia treatment

Intestinal schistosomiasis in preschool and school children residing along shores and on islands of Lake Victoria western Kenya: investigation of eosinophil cationic protein and fecal occult blood as potential markers for schistosomiasis induced bowel morbidity

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12844825

Enrollment

481

Registered

2022-05-10

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schistosomiasis Infections and Infestations Schistosomiasis [bilharziasis]

Interventions

At the beginning of the study, selected children will be checked for bilharzia by examining their stool and urine. Those with bilharzia will be followed for 18 months. All children with bilharzia will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Children enrolled in ECDs (PP1) and grade 4 in primary schools within Mbita Health and Demographic Surveillance System (HDSS), western Kenya 2. They should have stayed within the study site for the last 2 years and intend to stay for at least 2 more years

Exclusion criteria

Exclusion criteria: Those registered with other schistosomiasis studies

Design outcomes

Primary

Measure	Time frame
1. Fecal occult blood (FOB) measured by point of care (POC) chromatographic test assessed before and after praziquantel treatment at baseline, 6 months post-baseline and end-line 2. Eosinophil cationic protein (ECP) in stool measured by ELISA assessed before and after praziquantel treatment at baseline, 6 months post-baseline and end-line	—

Secondary

Measure	Time frame
Hemoglobin levels measured by POC Hemocue machine before and after praziquantel treatment at baseline, 6 months post-baseline and end-line	—

Countries

Kenya

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026